XML 85 R79.htm IDEA: XBRL DOCUMENT v3.20.1
Quarterly Financial Information (Unaudited) (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Disaggregation of Revenue [Line Items]                      
Total revenues $ 279,488 $ 866,863 $ 135,673 $ 2,829,905 $ 2,502,624 $ 2,000,868 $ 24,448,761 $ 1,529,644 $ 4,111,930 $ 30,481,897 $ 42,220,086
Research and development 22,003,955 19,137,209 22,486,266 24,389,888 26,365,647 21,851,858 22,462,620 24,577,751 88,017,319 95,257,876 98,572,618
General and administrative 8,696,586 5,681,441 5,850,101 6,975,029 5,636,141 6,791,693 7,189,310 9,698,015 27,203,156 29,315,159 28,290,369
Total operating expenses 30,700,541 24,818,650 28,336,367 31,364,917 32,001,788 28,643,551 29,651,930 34,275,766 115,220,475 124,573,035 125,862,987
Loss from operations (30,421,053) (23,951,787) (28,200,694) (28,535,012) (29,499,164) (26,642,683) (5,203,169) (32,746,122) (111,108,545) (94,091,138) (83,642,901)
Interest income 587,679 637,438 755,330 625,535         2,605,981 2,264,747 1,836,451
Interest expense (2,668,837) (2,428,671) (2,194,783) (656,248)         (7,948,539) 0 (25,933)
Interest and other income, net         (169,300) 380,987 396,681 312,523      
Change in fair value of common stock warrants         0 228,665 259,971 (127,841) 0 360,795 806,819
Change in fair value of derivative liability (4,315,105) 2,551,453 0 0         (1,763,652) 0 0
Loss on investment in affiliated entities (1,681,401) (485,841) (173,212) (750,103) (3,293,741) 1,017,359 (2,092,608) 2,380,423 (3,090,557) (1,988,567) (6,982,664)
Other income (expense), net 263,571 140,956 127,512 (35,839)         496,200 (1,343,856) (197,544)
Net loss before income tax benefit/(provision for income tax) (38,235,146) (23,536,452) (29,685,847) (29,351,667) (32,962,205) (25,015,672) (6,639,125) (30,181,017) (120,809,112) (94,798,019) (88,205,772)
Income tax benefit 87,764 0 106,771 62,800 0 0 0 (2,169,811) 257,335 (2,169,811) 0
Net loss (38,147,382) (23,536,452) (29,579,076) (29,288,867) $ (32,962,205) $ (25,015,672) $ (6,639,125) $ (32,350,828) (120,551,777) (96,967,830) (88,205,772)
Net loss attributable to non-controlling interest 485,344 445,759 191,850 69,605         1,192,558 0 0
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (37,662,038) $ (23,090,693) $ (29,387,226) $ (29,219,262)         $ (119,359,219) $ (96,967,830) $ (88,205,772)
Net loss per share                      
Basic ($ per share) $ (0.38) $ (0.23) $ (0.30) $ (0.30) $ (0.34) $ (0.27) $ (0.07) $ (0.36) $ (1.21) $ (1.05) $ (1.08)
Diluted ($ per share) $ (0.38) $ (0.25) $ (0.30) $ (0.30) $ (0.34) $ (0.27) $ (0.08) $ (0.36) $ (1.21) $ (1.05) $ (1.09)
Revenue under collaborative research and development arrangements                      
Disaggregation of Revenue [Line Items]                      
Total revenues $ 184,523 $ 617,427 $ 64,283 $ 2,770,712 $ 2,372,600 $ 1,813,287 $ 24,385,852 $ 1,289,046 $ 3,636,945 $ 29,860,785 $ 28,407,388
Revenue under collaborative research and development arrangements with affiliated entities                      
Disaggregation of Revenue [Line Items]                      
Total revenues 55,665 53,014 71,390 55,579 56,207 184,990 60,319 148,008 $ 235,649 $ 449,524 $ 765,828
Miscellaneous revenue, including from affiliated entities                      
Disaggregation of Revenue [Line Items]                      
Total revenues $ 39,300 $ 196,422 $ 0 $ 3,614 $ 73,817 $ 2,591 $ 2,590 $ 92,590